Page last updated: 2024-10-28

halothane and Chronic Hepatitis B

halothane has been researched along with Chronic Hepatitis B in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Patients with hepatocellular carcinoma with cirrhosis required intermediate end-tidal isoflurane concentrations; healthy live liver donors required the highest end-tidal isoflurane concentrations to provide sufficient anesthetic depth, as monitored by a target BIS (range, 45-55)."1.35Bispectral index monitoring in healthy, cirrhotic, and end-stage liver disease patients undergoing hepatic operation. ( Chen, CL; Chen, KH; Cheng, KW; Cheng, YF; Chiu, KW; Concejero, AM; Huang, CJ; Huang, TL; Jawan, B; Lin, CC; Liu, YW; Wang, CC; Wang, CH; Wang, SH, 2008)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, CH1
Chen, CL1
Cheng, KW1
Huang, CJ1
Chen, KH1
Wang, CC1
Concejero, AM1
Cheng, YF1
Huang, TL1
Chiu, KW1
Wang, SH1
Lin, CC1
Liu, YW1
Jawan, B1

Other Studies

1 other study available for halothane and Chronic Hepatitis B

ArticleYear
Bispectral index monitoring in healthy, cirrhotic, and end-stage liver disease patients undergoing hepatic operation.
    Transplantation proceedings, 2008, Volume: 40, Issue:8

    Topics: Adult; Aged; Anesthesia, Inhalation; Carcinoma, Hepatocellular; Halothane; Hepatitis B, Chronic; Hum

2008